| Verdine Picks Backers For FogPharma’s $66M Round, Keeping Firm Control | Ben Fidler | 05/16/18 | Boston |
| Refuge Bio Turns to China for $25M Financing of Precision CRISPR R&D | Frank Vinluan | 05/02/18 | San Francisco |
| Race to Mine Fungi for Drugs Revs up as Verdine’s LifeMine Gets $55M | Ben Fidler | 09/18/17 | Boston |
| Vivace Therapeutics Comes Out of Stealth With $25M for Cancer Drugs | Frank Vinluan | 06/28/17 | San Francisco |
| Third Rock’s Tango Aims For Drugs That Turn Cancer Against Itself | Frank Vinluan | 03/30/17 | Boston |
| Harvard’s Verdine Aims to Retire, Become Full-Time FogPharma CEO | Ben Fidler | 02/23/17 | Boston |
| Avelas Bio Raises $20M to Push Cancer-Illuminating Biologic Agent | Bruce V. Bigelow | 08/18/16 | San Diego |
| Same Twist, New Funding: Gene Synthesizer Raises $61M Series D | David Holley | 01/19/16 | San Francisco |
| Eyeing First Trials, Syros Brings in $40M and More Crossovers | Ben Fidler | 01/13/16 | Boston |
| East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More | Ben Fidler | 09/04/15 | Boston |
